BeyondtheCouch Posted - 39 minutes ago

$VKTX 76% of this stock is now owned by tutes! Shaking out retail for the tutes continues. Massachusetts Financial Services Co. MA acquired a new stake in Viking Therapeutics, Inc. The firm acquired 663,155 shares of the biotechnology company's stock, valued at approximately $12,341,000

okiejames Posted - 2 hours ago

$VKTX some people are so sensitive 😂😂😂

ShortingTheTrend Posted - 2 hours ago

$VKTX trade idea 💡 VXTX received a positive rating upgrade from Raymond James analyst Steven Seedhouse, with a revised price target of $116

BeyondtheCouch Posted - 3 hours ago

$VKTX these posters really annoy me. Super bullish when buying and praying it drops when they’ve got shaken out. Another one blocked

sterninvesting Posted - 3 hours ago

$VKTX when do the next data points come out? Is there any data coming out this week or next?

Chartsgalore Posted - 3 hours ago

$VKTX Forgot to mention that upcoming data release on VK2735 this quarter(by June) will more importantly show the feasibility of a once-a-month dosage, which is a big differentiating factor relative to other GLP-1's. This could actually be the biggest near-term catalyst

DG20 Posted - 3 hours ago

$VKTX I agree those prices are ‘possible’ but GIA is the LEAST likely of all scenarios. They are not in the process of adding staff and have made no mention of this option once especially when manufacturing/marketing would likely cost in excess of $5B. Most likely is a buyout between $135-270 (IMO $180-225/share). I’m sure Brian Lian can figure out how to make it with only several hundred million dollars. Partnership is also far more plausible…

Chartsgalore Posted - 3 hours ago

$VKTX 4 Big upcoming catalysts that you should be aware of: 1. Follow-up VK2735 from Phase 2 Venture trial(This will show how weight loss continued without plateauing while maintaining excellent safety(By the trajectory of weight loss at 13 weeks, we will likely see a headline # of more than 20% weight loss imo which could move the stock to ATH's, not exaggerating). 2. FDA Type C meeting for VKTX Phase 3, if no additional Phase 2 required, again stock moves BIG 3. Histologic data from biopsies at 52 Weeks released on VK2809 from Phase 2b Voyage trial in NASH/MASH. High probability of success with prior trial achieving primary endpoint(85% of patients achieved 30% or greater liver fat reduction with placebo-like safety profile 4. VK0214 data release from Phase 1b trial(double-blinded, placebo-controlled, multi-center) in rare disease Adrenomyeloneuropathy, which has no available treatment on market. Prior Phase 1 study showed reduction in LDL, Triglycerides, ApoB, and LipoA, exc safety

fmalad Posted - 4 hours ago

$VKTX no buyout! Everyone thinks they can bought for 115-150 . Management knows that down the road it’s a 800-1000 stock! No brainer for Viking to go at it alone and wait for the 1000 price! Why would u want to be a millionaire when u could be a billionaire!

okiejames Posted - 4 hours ago

$VKTX could this fill the gap? Daily and weekly look super bearish

Phil7777777777 Posted - 6 hours ago

$VKTX

Phil7777777777 Posted - 6 hours ago

$VKTX

Phil7777777777 Posted - 6 hours ago

$VKTX

SwingJoy1 Posted - 7 hours ago

$VKTX looking forward to Tuesday

BiotechJohn Posted - 11 hours ago

@DG20 Additionally, the small number of patients and the short duration of the $VKTX trial make it difficult to draw definitive conclusions on safety. The FDA will likely require much larger and longer trials, which can take several years. Approval in just 18 months is highly optimistic, especially without a Phase 3 trial even started. Moreover, semaglutide has cardiovascular data, implying that $VKTX would need another extensive and expensive trial to match this. Given the FDA review alone will take over a year, the timeline for approval is much longer.

TrustButVerifi Posted - 12 hours ago

$VKTX 30 X. . For all those short sighted nay sayers , all these multiple bagging predictions were done for the likes of Amazon, Regeneron , Gilead.many other tickers. I recall arguing those types of multiple about Amazon with a Cisco employee 28 years ago who thought he was brighter than Jeff Bozo. Lol

TrustButVerifi Posted - 13 hours ago

$vktx when u post your print and close out then u can boast. Til then STFU! The only hand and fist is the one u re sittin on!

TrustButVerifi Posted - 13 hours ago

$VKTX Crappy just gets deeper and deeper here by the minute! This goober thinks he can time the stock on a daily basis. Dumbest fk I ve ever seen on this thread beside the one who showed up here stating Viking needs to do a secondary because they have 55 mil in cash. And then we have 20 yr biotech John Doe who after 20 years just discovered this company and has no position in the stock but thinks the company is overpriced. U can’t make this Chet up! It s just laughable how fkn stupidity never ends! Not sure which is worse the fool who says he is gonna cover at 59 or the other fool who says he doesn’t have a position but is giving this thread advice on valuation of a biotech who by most prominent biotech analyst have a target of almost 100% from this level.

DG20 Posted - 15 hours ago

$VKTX I’m so glad you pointed this out. Humira, Lipitor, Plavix and Eliquis are 4 of the largest selling drugs in history (each was the best seller of their respective drug class as well) and NONE of them were close to first to market…

DG20 Posted - 15 hours ago

$VKTX Again another post NOT related to VKTX. Viking is making its own drug not a bio similar as a generic competitor. Viking has already created VK2735 and is studying it. VK2735 is likely 18-30 months from FDA APPROVAL… ———Oh what a tangled web we weave when first we practice to deceive———

Ohzipit Posted - 16 hours ago

$VKTX here it is again!

BeyondtheCouch Posted - 16 hours ago

$VKTX Very interesting that Roche could have shown data which would have enabled everyone to see a true comparison to VK2735 - but they chose not to

BeyondtheCouch Posted - 16 hours ago

$VKTX Yes, it’s detailed in Raymond James analyst note. Roche “games” resulted in RJ increasing Viking to Strong Buy $116 PT

Jackie_O_ Posted - 17 hours ago

$VKTX I have a quiz for the thread. Most biopharmaceutical buyouts occur predominantly in which 2 phases of a biopharmaceutical assets life cycle? A.) Pre-clinical B.) Phase 1 C.) Phase 2 D.) Phase 3 E.) Post Approval

ChappiesWorld Posted - 18 hours ago

$VKTX

Jackie_O_ Posted - 19 hours ago

$VKTX Best...In...Class 🏆👍🥰

venkygn Posted - 20 hours ago

$VKTX Average Target Price 112.35

kellyCriterion101 Posted - 21 hours ago

$VKTX It has been +2 mo. since February 27th. The company ideally submitted a request for a type B meeting with the agency on Feb 27 or 28. It has been over 75 days now, whereas meetings in the agency usually occur 60-75 days after requested. Has the company updated investors on where they stand with the status of getting a meeting? What's the last update on this meeting?

Ripper0811 Posted - 21 hours ago

$VKTX Hope this runt below does not delete this one.

Ripper0811 Posted - 21 hours ago

$VKTX Every stock gets one of these freaks at about this time who are stalwarts who discovered America 200 years after Columbus did.